bFGF (basic fibroblast growth factor) is used in scar serums because it actively prevents the formation of myofibroblasts—the cells primarily responsible for excessive scarring—by blocking their differentiation through the Notch1/Jagged1 signaling pathway. This mechanism directly reduces both the thickness and discoloration of scars by fundamentally altering how your skin heals itself.
For example, clinical studies using bFGF-containing products like Fiblast® spray showed significant improvements in scar appearance and color matching when applied after wound debridement or skin grafting. Unlike topical treatments that merely soften existing scar tissue, bFGF works upstream in the healing process to prevent pathological scar formation from occurring in the first place. This article explains the science behind bFGF’s effectiveness, how it restructures collagen, the clinical evidence supporting its use, current limitations, and why it’s found in premium scar treatment serums despite being less commonly known than silicone or niacinamide.
Table of Contents
- How Does bFGF Actually Prevent Scars During the Healing Process?
- The Collagen Restructuring Effect—Why Scars Become Softer and Flatter
- Clinical Evidence: What the Research Actually Shows About bFGF’s Effectiveness
- How bFGF Functions Inside Scar Treatment Serums and Skincare Products
- The Stability Challenge—Why bFGF Is Difficult to Formulate and What Companies Do About It
- bFGF vs. Other Growth Factors and Anti-Scar Ingredients—How Does It Compare?
- Current Clinical Use and the Future of bFGF in Scar Management
- Conclusion
How Does bFGF Actually Prevent Scars During the Healing Process?
The key to bFGF’s anti-scar effect lies in blocking myofibroblast differentiation at the cellular level. When tissue is injured, epidermal stem cells normally differentiate into myofibroblasts—specialized cells that contract and generate the dense, rigid collagen that creates a visible scar. bFGF intercepts this process by activating the Notch1/Jagged1 signaling pathway, essentially telling your skin cells to remain in their current state instead of transforming into scar-forming myofibroblasts. This happens through the activation of two critical molecular signaling systems: the MEK/ERK pathway and the PI3K/Akt pathway, which together communicate to stem cells that scar formation should be suppressed.
The earlier in the wound-healing timeline that bFGF reaches the injury site, the more effectively it can prevent scars from forming. This is why bFGF is most effective when applied immediately after wound debridement or during the first stages of wound healing, rather than being used on mature scars that have already formed. Once myofibroblasts have already differentiated and begun laying down excessive collagen, bFGF becomes less effective at reversing that process. For acne scars specifically, this creates a practical challenge: most people don’t apply bFGF serums during active acne healing but rather months or years afterward, when the scar is already established. However, bFGF can still help by promoting the remodeling of existing scar tissue through other mechanisms (discussed in the next section), making it useful even on older scars.
The Collagen Restructuring Effect—Why Scars Become Softer and Flatter
Beyond preventing myofibroblast formation, bFGF also remodels the collagen structure in existing scar tissue through a shift in collagen composition. bFGF treatment decreases expression of collagen Type I—the dense, rigid protein that gives scars their hardened, raised appearance—while simultaneously increasing collagen Type III expression, which is more flexible and organized. This rebalancing of the collagen III-to-Type I ratio is significant because it means that treated scars don’t just become less visible; they physically change from stiff, inelastic tissue into skin that moves and feels more normal. Studies measuring collagen density in bFGF-treated wounds found substantially reduced collagen accumulation compared to untreated wounds, demonstrating that the effect is measurable and reproducible.
This collagen-remodeling effect is amplified by bFGF’s ability to increase expression of matrix metalloproteinase-1 (MMP-1), an enzyme that actively breaks down excess collagen and scar tissue. Essentially, bFGF doesn’t just prevent new scar formation and rebalance collagen types—it also recruits your skin’s own enzymatic machinery to dissolve existing scar collagen. However, this effect is moderate and gradual. On very mature, fibrous scars (those present for several years), the collagen has become cross-linked and stabilized, making it more resistant to enzymatic breakdown. This is why bFGF serums work better on relatively fresh scars or actively healing skin damage rather than on decades-old scars, though improvement is still possible in many cases.
Clinical Evidence: What the Research Actually Shows About bFGF’s Effectiveness
The strongest evidence for bFGF comes from Japan, where recombinant topical bFGF has been approved for skin ulcer and wound treatment since 2001—making it the longest-standing clinical application of this growth factor for wound healing globally. This 20+ year clinical history provides substantial real-world data on both effectiveness and safety. In animal models, bFGF promoted wound healing and reduced both flattened non-pathological scars in rat skin wounds and hypertrophic scars in rabbit ear models, demonstrating consistent anti-scar effects across different tissue types.
In human clinical trials, Fiblast® spray—a bFGF product—showed significant improvements when applied immediately after wound debridement and before skin grafting. Patients treated with bFGF had better scar quality and improved graft color match compared to control groups, suggesting that the anti-scar effects seen in animal studies translate to humans. These aren’t marginal improvements either; the difference between bFGF-treated and untreated wounds was substantial enough to be clinically meaningful. The limitation here is that most rigorous studies involve acute wound scenarios (post-surgery, post-grafting) rather than chronic acne scarring, so extrapolating the results directly to older atrophic or hypertrophic acne scars requires some caution, though the underlying mechanisms remain relevant.
How bFGF Functions Inside Scar Treatment Serums and Skincare Products
When bFGF is incorporated into topical serums, it must reach viable cells in the epidermis and dermis to exert its anti-scar effects. This creates a formulation challenge because bFGF is a protein, and proteins cannot penetrate the skin barrier as effectively as small molecules. To overcome this, manufacturers use bFGF at concentrations ranging from nanograms to low micrograms per milliliter, often delivered through enhanced penetration systems. Some products combine bFGF with humectants, peptides, or skin-penetration enhancers to help the growth factor reach deeper skin layers where myofibroblasts reside.
In practice, scar serums with bFGF are typically applied once or twice daily to clean, dry skin over the scarred area. The treatment timeline for noticeable results usually spans 8-12 weeks, as the mechanism of action depends on cellular signaling and collagen remodeling rather than instantaneous chemical reactions. Users comparing bFGF serums to other anti-scar products like silicone gels or niacinamide serums should expect that bFGF works through a fundamentally different biological pathway—it’s not smoothing the surface of the scar but rather changing the cellular behavior underlying scar formation. This makes bFGF particularly useful in combination therapy, where it can be layered under silicone products or applied alongside retinoids that promote additional collagen turnover.
The Stability Challenge—Why bFGF Is Difficult to Formulate and What Companies Do About It
The most significant practical limitation of bFGF in skincare products is its instability. Recombinant bFGF is a protein that degrades rapidly under physiological conditions—exposed to heat, light, pH changes, and enzymatic breakdown, bFGF loses its biological activity relatively quickly. This is why clinical applications of topical bFGF are substantially limited by stability issues, and why manufacturers must employ sophisticated delivery systems to keep bFGF active until it reaches your skin. The solution involves encapsulating bFGF in protective carriers such as liposomes, hydrogels, or protein nanoparticles made from human serum albumin or similar biocompatible materials.
When evaluating a bFGF serum, product stability is critical to efficacy. A bFGF serum that has been sitting on a shelf for months without proper stabilization or storage conditions may contain degraded, inactive bFGF—you’d be applying a useless product. This is why high-quality bFGF products typically require cool storage (refrigeration or below 25°C), airtight, light-protective packaging, and may have shorter shelf lives than conventional serums. Some manufacturers add antioxidants like vitamin E or ferulic acid to protect bFGF from oxidative breakdown. The trade-off is clear: bFGF serums are more expensive, require more careful storage, and have shorter usable lifespans than simpler, more stable anti-scar ingredients, but the biological mechanism justifies the extra effort when formulated correctly.
bFGF vs. Other Growth Factors and Anti-Scar Ingredients—How Does It Compare?
bFGF is one of several growth factors being studied for scar reduction, but it’s distinct in its specific mechanism. While other growth factors like TGF-beta promote myofibroblast formation and collagen deposition (actually worsening scarring), bFGF actively suppresses myofibroblast differentiation—a fundamentally protective approach. Platelet-derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) focus primarily on angiogenesis and tissue remodeling without the specific anti-myofibroblast action that bFGF provides. In head-to-head comparisons, bFGF shows particularly strong effects on hypertrophic and keloid scar prevention, though it’s less commonly encountered in consumer skincare than ingredients like silicone, niacinamide, or retinoids, largely due to formulation complexity and stability challenges.
Unlike topical steroids (which reduce inflammation but don’t address the underlying collagen remodeling), bFGF works through biological signaling rather than immune suppression. Unlike laser treatments or microneedling (which work through controlled injury and cellular response), bFGF works biochemically to prevent the problematic cellular differentiation that causes scars in the first place. This makes bFGF complementary to other anti-scar approaches rather than a replacement. For someone with active acne-prone skin, combining a bFGF serum with a retinoid and sun protection may address both the prevention of new scar formation and the remodeling of existing scars through multiple mechanisms.
Current Clinical Use and the Future of bFGF in Scar Management
Currently, bFGF is most established in clinical and medical settings—particularly in Japan, South Korea, and other Asian markets where Fiblast® and similar products have been used for decades in wound care and post-surgical scar prevention. In North America and Europe, bFGF is less common in over-the-counter skincare products, in part because regulatory approval for growth factors in cosmetics is more stringent, and the commercial market for bFGF serums is smaller. However, interest in bFGF is growing as consumers and dermatologists become more aware of the molecular mechanisms behind scarring and as formulation technologies improve.
The future of bFGF in skincare likely involves continued refinement of delivery systems—newer research into protein nanoparticles, peptide analogs that mimic bFGF’s signaling without being as unstable, and combination formulations that pair bFGF with complementary ingredients that enhance collagen remodeling. The long clinical history in Japan demonstrates that bFGF is safe and effective when properly formulated, removing the novelty factor and validating its use. As formulation costs decrease and stability improves, bFGF serums may become more mainstream in anti-scar skincare, offering a scientifically grounded alternative to unproven anti-scar products.
Conclusion
bFGF is used in scar serums because it addresses scarring at the cellular level by preventing myofibroblast differentiation through the Notch1/Jagged1 signaling pathway, while simultaneously rebalancing collagen composition and promoting enzymatic breakdown of excess scar tissue. The mechanism is scientifically validated through over two decades of clinical use in Japan and supported by animal and human studies demonstrating significant improvements in scar quality, texture, and appearance. Unlike passive scar-softening ingredients, bFGF actively intervenes in the scarring process itself.
If you have active scars or are prone to keloid or hypertrophic scar formation, a bFGF serum may be worth considering alongside dermatologist-recommended treatments. Look for products with stabilized bFGF in protective formulations, proper cool storage instructions, and realistic timelines of 8-12 weeks for visible results. For older, deeply established scars, bFGF works best as part of a comprehensive approach combining retinoids, professional treatments like microneedling, and sun protection—but its specific anti-myofibroblast action makes it uniquely valuable in the early stages of wound healing and scar prevention.
